Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration (vol 126, pg 4390, 2020)

Por: Molto, C, Hwang, TJ, Borrell, M, Andres, M, Gich, I, Barnadas, A, Amir, E, Kesselheim, AS, Tibau, A

---

Publicada: 1 sep 2021 Ahead of Print: 1 jun 2021

---

---

Filiaciones:
Molto, C:
 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Hosp Santa Creu & St Pau, Oncol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Med, Barcelona, Spain

Hwang, TJ:
 Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States

Borrell, M:
 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Hosp Santa Creu & St Pau, Oncol Dept, Barcelona, Spain

Gich, I:
 Department of Epidemiology, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain

Barnadas, A:
 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Hosp Santa Creu & St Pau, Oncol Dept, Barcelona, Spain

Tibau, A:
 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Hosp Santa Creu & St Pau, Oncol Dept, Barcelona, Spain